EMEA-001441-PIP03-17

Key facts

Active substance
semaglutide
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0007/2019
PIP number
EMEA-001441-PIP03-17
Pharmaceutical form(s)
Concentrate for solution for injection
Condition(s) / indication(s)
Treatment of obesity
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Novo Nordisk A/S
Denmark
Tel. +45 44448888
E-mail: paediatrics@novonordisk.com
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating